T7741

DS-1001b is an inhibitor of mutant IDH-1 (Isocitrate Dehydrogenase-1)

Opicinumab (BIIB033) is a novel monoclonal antibody against LINGO-1 that may be used to prevent and delay acute optic neuritis and recurrent multiple sclerosis.

Ontamalimab is a highly specialized fully human monoclonal antibody target mucosal addressin cell adhesion molecule-1 (MAdCAM-1), inhibition of lymphocyte homing to the gastrointestinal mucosa by disrupting the interaction between MAdCAM-1 and the α 4 β 7 integrin across various inflammatory models.

Lupartumab (BAY 1112623) is a monoclonal antibody targeting LYPD3 (C4.4A) and is employed in the synthesis of antibody-active molecular couplers for studying LYPD3-associated tumor diseases.

RG7841 is a humanized antibody targeting Ly6E, which can be used to study lung cancer.

Samrotamab (PR-1498487) is a humanized anti-LRRC15 antibody that can be used to synthesize the ADC compound (Samrotamab vedotin).

LadiratuzumAb (hLIV22) is a humanized monoclonal antibody targeting LIV-1/ZIP6.LadiratuzumAb is a naked antibody to SGN-LIV1A and is capable of synthesizing an antibody-activated molecule coupling (ADC), SGN-LIV1A.LadiratuzumAb can be used for the prevention and treatment of breast cancer.

MSC-1 (Anti-LIF Antibody) is a humanized anti-leukemia inhibitory factor (LIF) monoclonal antibody that acquires anti-tumor and pro-inflammatory functions in a homozygous colon cancer mouse model and can be used to study advanced solid tumors.